Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Isis' financing vehicle supports CV/metabolic development

Executive Summary

In a deal expected to last four years, antisense drug developer Isis Pharmaceuticals has licensed intellectual property related to its cholesterol candidate ISIS301012 and two diabetes programs to Symphony GenIsis, an off-balance sheet entity that was formed by a $75mm investment from private equity company Symphony Capital and other co-investors.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Special-Purpose Financing Vehicle
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register